All authors critically revised the manuscript for important intellectual content and approved the final version to be submitted
Was this newsletter forwarded to you
Do not exceed the recommendeddailydose
Apovian, MD, FTOS, co-director, Center for Weight Management and Wellness and professor of medicine at Harvard Medical School in Boston, Mass., commented, Once we have shown that anti-obesity agents notably GLP-1 and combinations thereof lower cardiovascular risk, we can then demand universal insurance coverage of these agents
Wegovy usage in Manitoba continues to surge, with over 88,000 claims for treatments like Wegovy in the province just between 2024 and 2025